A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination
Dennis Morrison, Sandip Roy, Craig Rayner, Ahmed Amer, Dan Howard, James R Smith, Thomas G Evans, Dennis Morrison, Sandip Roy, Craig Rayner, Ahmed Amer, Dan Howard, James R Smith, Thomas G Evans
Abstract
The threat of potential pandemic influenza requires a reevaluation of licensed therapies for the prophylaxis or treatment of avian H5N1 infection that may adapt to man. Among the therapies considered for use in pandemic influenza is the co-administration of ion channel and neuraminidase inhibitors, both to potentially increase efficacy as well as to decrease the emergence of resistant isolates. To better understand the potential for drug interactions, a cross-over, randomized, open-label trial was conducted with amantadine, 100 mg po bid, and oseltamivir, 75 mg po bid, given alone or in combination for 5 days. Each subject (N = 17) served as their own control and was administered each drug alone or in combination, with appropriate wash-out. Co-administration with oseltamivir had no clinically significant effect on the pharmacokinetics (PK) of amantadine [mean ratios (90% CI) for AUC(0-12) 0.93 (0.89, 0.98) and C(max) 0.96 (0.90, 1.02)]. Similarly, amantadine co-administration did not affect oseltamivir PK [AUC(0-12) 0.92 (0.86, 0.99) and C(max) 0.85 (0.73, 0.99)] or the PK of the metabolite, oseltamivir carboxylate [AUC(0-12) 0.98 (0.95, 1.02) and C(max) 0.95 (0.89, 1.01)]. In this small trial there was no evidence of an increase in adverse events. Although many more subjects would need to be studied to rule out a synergistic increase in adverse events, the combination in this small human drug-drug interaction trial appears safe and without pharmacokinetic consequences.
Trial registration: ClinicalTrials.gov NCT00416962.
Conflict of interest statement
Competing Interests: All of the authors except D. Morrison are employees of the two companies, Roche and Novartis, that jointly financed this study.
Figures
References
- Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374–1385.
- Hayden FG. Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res. 2006;71:372–378.
- Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. Jama. 2006;295:891–894.
- Hayden F, Klimov A, Tashiro M, Hay A, Monto A, et al. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther. 2005;10:873–877.
- Ilyushina NA, Govorkova EA, Webster RG. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology. 2005;341:102–106.
- Govorkova EA, Fang HB, Tan M, Webster RG. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother. 2004;48:4855–4863.
- Hayden FG, Douglas RG, Simons R. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother. 1980;18:536–541.
- Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 2006;70:121–131.
- Wilson SZ, Knight V, Wyde PR, Drake S, Couch RB. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother. 1980;17:642–648.
- Ison MG, Gnann JW, Nagy-Agren S, Treannor J, Paya C, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther. 2003;8:183–190.
- Wiltshire H, Citron A, Clarke T, Serpe C, Gray D, Herron W. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of RO-64-0802, an anti-influenza drug, and its prodrug, oseltamivir, in human and animal plasma and urine. J Chromatographr B Biomed Sci Appl. 2000;745:373–388.
- Schentag JJ, Hill G, Chu T, Rayner CR. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian Subjects. J Clin Pharmacol. 2007;47:689–690.
- Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988;14:35–51.
- Doucette KE, Aoki FY. Oseltamivir: a clinical and pharmacological perspective. Expert Opin Pharmacother. 2001;2:1671–1683.
- Webster RG, Govorkova EA. H5N1 influenza–continuing evolution and spread. N Engl J Med. 2006;355:2174–2177.
- Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005;55(Suppl 1):i5–i21.
- de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353:2667–2672.
- Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005;437:1108.
Source: PubMed